Global Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, POC, HPLC) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global sickle cell screening and testing market was worth USD 223.04 millions in 2019. It is projected to grow at a compound annual rate (CAGR of 5.44%) between 2020 and 2027. Hemoglobinopathies are a group of disorders that can be inherited. The sickle cell disease (SCD), which occurs when abnormal hemoglobin damage and deforms RBCs, is one example. Millions of people worldwide are affected by sickle cell disease. It is most prevalent in sub-Saharan Africa and the Western Hemisphere region. It is important to detect sickle cell disease early as there is not an easily accessible or widely available treatment.

SCD has been neglected as a global health concern. This is especially true in developing countries where there have been an increase in disease incidence. This can be attributed to a lack of awareness by patients/public and healthcare policymakers working in these regions.

Market growth will be boosted by government initiatives to support diagnosis. In March 2020, the National Institutes of Health launched a Technology Accelerator Challenge, with a USD 1 million prize, to encourage the development of point-of-care diagnostics. This challenge is focused on diseases with high health impacts, such as anemia, sickle cell disease and malaria.

Pilot-scale implementation of newborn screening programs has been made in several countries with sickle cell anemia, including Benin, Ghana, Democratic Republic of the Congo (DRC), Kenya and Kenya. These countries have successfully fought the disease. This has encouraged developing economies to establish newborn screening programs. This will further boost market growth.

The development of digital, non-invasive, handheld and digital technologies that facilitate the detection and management of sickle cell disease is a key step in the removal of barriers to targeted sickle cell diagnosis. The current POC devices are based upon methods such as microfluidic electrophoresis, lateral flow immunoassay and densitometry.

Companies are working to develop point-of-care test that is portable, affordable, sensitive, specific, and specific for HbA, HbC and HbS. The priority of newborn/neonatal testing will help in the sustainable scaling-up and delivery of key therapeutic and diagnostic interventions for sickle cells disease.

Technology Insights

Hemoglobin electrophoresis was the dominant market player in 2019, with 38.9%. In the next few years, the point-of-care segment will grow at a rapid pace. Due to increased use of commercialized tests, lateral flow assays accounted for a significant share. Both paper-based and smartphone-based assays will see significant developments. This will boost the growth of point-of-care technology.

To distinguish between hemoglobinopathies, it is important to determine the exact diagnosis by analyzing hemoglobin samples from patients. These hemoglobinopathies include homozygous and heterozygous sickle cells anemias (HbSS), beta-thalassemias (HbSC), and HbSS disease. SCD testing can be done using two basic methods: solubility and sickling tests.

These tests are easier to use, but they can't distinguish between HbSA and beta-thalassemias, HbSS or HbSC characteristics in patients. Additional tests have been developed that can confirm sickle hemoglobin variants in carriers and positive patients. These include hemoglobin electrophoresis (HPOLC), high-performance liquidchromatography (HPLC), molecular tests, and isoelectric focus (IEF).

Age Group Insights

With a market share of 53.4%, newborn screening dominated the global market for revenue in 2019, Adult screening is expected to grow at the fastest rate of CAGR over the forecast period. SCD management and treatment differ depending on the stage of the patient. This can be attributed to differences in SCD-related pain, comorbidities and psychosocial impact as well as healthcare expenditure, with respect to sickle cell patients of different ages.

A growing number of research projects are also aimed at studying the effects of age-specific healthcare strategies on the management of sickle cells disease. Targeted screening of sickle cells patients by age has helped to extend the life expectancy of these patients. Additionally, the evaluation of specific challenges faced by sickle cell patients can help in developing patient-specific diagnostic and therapeutic interventions.

Surveys of sickle cell patients with symptoms show that patients with sickle cells are more likely to be older and to have more comorbidities. This is a major boost to the adult testing market.

Sector Type Insights

With a market share of 42.8%, the government laboratories led and will continue to lead the market for the duration of the forecast period. Over the forecast period, the PPP sector will experience the fastest CAGR at 6.35%. Sickle cell disease testing involves two stages. First, patients are tested in a medical setting. Then confirmatory testing or follow up screening is done to verify that the patient was screened.

This preliminary screening and confirmatory testing is currently performed in hospitals, medical centers, and other facilities that are affiliated with the government, private sector, commercial sectors, or NGOs. The demand for sickle-cell anemia screening is expected to rise due to the active participation of these sectors.

Regional Insights

North America dominated the market in 2019, with a 27.0% share. The market is dominated by North America with a share of 27.0% in 2019. Newborn screenings are conducted in all 50 states in the United States and in 8 Canadian provinces. This has created a favorable climate for companies that operate in the market.

In developing countries, such as Africa or Asia, there are well-established criteria for creating and implementing sickle cells disease neonatal screening programmes. Sickle cell screening programs are highly recommended for regions where the disease incidence rate is less than 0.05%. These screening programs can be used to screen all newborns who have hemoglobin C and sickle cells.

The lack of adequate facilities for newborn screening programs means that very few countries currently have newborn screening programs in place. Recent evidence of a rising recognition and acceptance of sickle cell screening for newborns has been seen in Asia Pacific countries, particularly India.

These developing countries are also working on strategies to tackle the challenges of newborn screening programs in high-income countries. This includes streamlining follow up screening and diagnosis. This will be a major boost for the Asia Pacific market in near future.

Market Share Insights & Key Companies

Market leaders are contributing to market growth by collaborating and expanding their businesses in order to increase market share. Companies are also developing sickle cell (HbS), screening and testing specific to research needs. This will increase screening product adoption. The following are some of the major players in the global sickle-cell anemia screening and testing market:

• STRECK, INC.

• Daktari Diagnostics

• BIOMEDOMICS INC.

• Laboratory Corporation of America Holdings

• Ask for a Test, Ltd.

• HALCYON BIOMEDICAL INORPORATED

• Silver Lake Research Corporation

• HEMOTYPE

• HEMEX HEALTH

• Bio-Rad Laboratories Inc.

• PerkinElmer Inc.

• Quest Diagnostics

Up Market Research published a new report titled “Sickle Cell Anemia Testing & Screening Market research report which is segmented by Technology (Hemoglobin Electrophoresis, POC, HPLC), By Players/Companies HEMOTYPE, PerkinElmer Inc, HEMEX HEALTH, BIOMEDOMICS INC, Daktari Diagnostics, HALCYON BIOMEDICAL INCORPORATED, Laboratory Corporation of America Holdings, Request A Test Ltd, Bio-Rad Laboratories Inc, STRECK INC, Silver Lake Research Corporation, Quest Diagnostics”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Sickle Cell Anemia Testing & Screening Market Report Segments:

The market is segmented by Technology (Hemoglobin Electrophoresis, POC, HPLC).

Sickle Cell Anemia Testing & Screening Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Sickle Cell Anemia Testing & Screening Market

Overview of the regional outlook of the Sickle Cell Anemia Testing & Screening Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Sickle Cell Anemia Testing & Screening Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Sickle Cell Anemia Testing & Screening Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Hemoglobin Electrophoresis

                2. POC

                3. HPLC

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Sickle Cell Anemia Testing & Screening Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Sickle Cell Anemia Testing & Screening Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.